Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of domagrozumab in boys with Duchenne muscular dystrophy
NCT02907619Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Oct 2016
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of domagrozumab in Duchenne muscular dystrophy (DMD), sponsored by Pfizer. Primary endpoints: Number of Participants With Severe Treatment-Emergent Adverse Events (TEAEs) at 2 Years, Number of Participants With Laboratory Test Abnormalities at 2 Years and 12 more. Started Oct 2016; status: terminated.
02
Drugs
domagrozumab
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02907619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02907619.